Education
About Us
Working with TipRanks
Follow Us
Illumina (ILMN)
NASDAQ:ILMN
ILMN Stock Chart & Stats
$123.54
-$1.43(-1.02%)
At close: 4:00 PM EST
$123.54
-$1.43(-1.02%)
Day’s Range― - ―
52-Week Range$68.70 - $156.66
Previous CloseN/A
Volume388.94K
Average Volume (3M)1.68M
Market Cap
$18.99B
Enterprise ValueN/A
Total Cash (Recent Filing)$1.28B
Total Debt (Recent Filing)$2.50B
Price to Earnings (P/E)27.6
Beta1.32
Next Earnings
Feb 05, 2026EPS Estimate
1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.34
Shares Outstanding153,700,000
10 Day Avg. Volume1,475,094
30 Day Avg. Volume1,683,153
Financial Highlights & Ratios
PEG Ratio-3.75
Price to Book (P/B)8.95
Price to Sales (P/S)4.86
P/FCF Ratio29.95
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$115.00Price Target Upside-6.91% Downside
Rating ConsensusHold
Number of Analyst Covering17
Bulls Say, Bears Say
Bulls Say
Clinical Consumables GrowthIllumina's clinical consumables revenue continued to accelerate, increasing to +12% y/y as clinical customers transition to the NovaSeq X.
Guidance And ExpectationsThe company raised operating margin and EPS guidance to reflect Q3 outperformance and change in China revenue expectation.
Revenue PerformanceIllumina now expects $220 million in revenue from China in 2025, compared to prior guidance of $190-210 million.
Bears Say
Competitive ThreatThe company's management is underestimating the competitive threat, particularly from competitors like Roche/Axelios, which could impact future performance.
Pricing And ProfitabilityIncremental competition is likely to pressure the company to increase operational expenses and remain aggressive on pricing, which could impact profitability.
Transition HeadwindsThe company is expected to face 'transition headwinds' for another 2-4 quarters, which could pose risks to future performance.
Illumina News
ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was $68.70 and its highest was $156.66 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $18.99B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Feb 05, 2026 which is in 94 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Oct 30, 2025. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.168 by $0.172.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Overvalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.2.
How many shares outstanding does Illumina have?
Illumina has 153,700,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of $1.34 in its last earnings report, beating expectations of $1.168. Following the earnings report the stock price went up 24.775%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in ILMN
Illumina Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$115.00 (-6.91% Downside)
$115.00 (-6.91% Downside)
Blogger Sentiment
Bullish
ILMN Sentiment 80%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 81.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.29%
12-Months-Change
Fundamentals
Return on Equity
31.20%
Trailing 12-Months
Asset Growth
0.10%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. (ILMN) is a leading developer and manufacturer of life sciences tools and integrated systems for the analysis of genetic variation and function. Founded in 1998 and headquartered in San Diego, California, Illumina specializes in next-generation sequencing (NGS) technology, genotyping, and microarray solutions. Its products are primarily used in genomics research, clinical applications, and agricultural biotechnology, enabling advancements in personalized medicine, diagnostics, and drug discovery.
ILMN Company Deck
ILMN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical markets and the NovaSeq X transition, with revenue and earnings exceeding expectations. However, challenges in research markets and ongoing issues in China present hurdles. Despite these challenges, the company remains optimistic about its strategic initiatives and future growth.View all ILMN earnings summariesILMN Revenue Breakdown
72.16% Consumables
16.38% Service and other revenue
11.46% Instruments
ILMN Stock 12 Month Forecast
Average Price Target
$115.00
▼(-6.91% Downside)
Technical Analysis
Ownership Overview
2.77% Insiders
27.57% Mutual Funds
0.35% Other Institutional Investors
46.50% Public Companies and Individual Investors